Clin Orthop Surg.  2018 Jun;10(2):225-233. 10.4055/cios.2018.10.2.225.

Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors

  • 1Department of Surgery, Lin Women's Hospital, Seoul, Korea.
  • 2Division of Orthopaedic Surgery, Glasgow Royal Infirmary, Glasgow, UK.
  • 3Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
  • 4Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 5Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.


We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables.
Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months.
Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years.
The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.


Extra-abdominal desmoid tumors; Nonsteroidal anti-inflammatory drug

MeSH Terms

Cyclooxygenase 2
Fibromatosis, Aggressive*
Response Evaluation Criteria in Solid Tumors
Retrospective Studies
Cyclooxygenase 2
Full Text Links
  • CIOS
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error